GoodRx expects Pharma Direct revenue growth of at least 30% in 2026 amid shift to pharma manufacturer solutions

GoodRx anticipates at least 30% revenue growth in its Pharma Direct segment by 2026, driven by a strategic shift towards pharmaceutical manufacturer solutions.